We demonstrated that mesotheliomas responded to CSF1R inhibition by upregulating their PDL1 expression and that combining the CSF1Ri with a PDL1 inhibitor was more effective in retarding mesothelioma growth compared to each monotherapy. Here, CSF1R is linked to mesothelioma.